微結晶セルロース市場は予測期間中、大幅な拡大が予想され、医薬品賦形剤としての MCC への関心の高まりが成長要因になります。さらに、食品＆飲料業界の台頭、購入者の生活様式の変化、一人当たりの裁量キャッシュフローの伸び、および個人の購買力の拡大によって、予測期間中に微結晶セルロース市場は最大の成長が見込まれます。一方で、微結晶性セルロース代替品の入手可能性が、この市場の発展を妨げる可能性があります。
目次
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVENESS ANALYSIS
1.1.1 GLOBAL MICROCRYSTALLINE CELLULOSE MARKET, BY SOURCE
1.1.2 GLOBAL MICROCRYSTALLINE CELLULOSE MARKET, BY END-USE INDUSTRY
1.1.3 GLOBAL MICROCRYSTALLINE CELLULOSE MARKET, BY REGION
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 TOP-DOWN AND BOTTOM-UP APPROACH
3.6 FORECAST MODEL
3.7 LIST OF ASSUMPTIONS
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING DEMAND OF MICROCRYSTALLINE CELLULOSE IN PHARMACEUTICAL INDUSTRY
4.2.2 SUSTAINABLE GROWTH OF DEMAND IN PROCESSED FOOD INDUSTRY
4.3 RESTRAINT
4.3.1 AVAILABILITY OF SUBSTITUTES
4.4 OPPORTUNITIES
4.4.1 DEVELOPMENT AND USE OF NON-WOOD BASED MICROCRYSTALLINE CELLULOSE IN THE GLOBAL MARKET
4.4.2 INCREASING USE OF MICROCRYSTALLINE CELLULOSE FOR COSMETICS AND PERSONAL CARE PRODUCTS
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 RAW MATERIAL SUPPLIERS
5.1.2 MICROCRYSTALLINE CELLULOSE MANUFACTURERS
5.1.3 DISTRIBUTION & SALES CHANNEL
5.1.4 END USE
5.2 PORTER’S FIVE FORCES ANALYSIS
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 INTENSITY OF COMPETITIVE RIVALRY
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF SUPPLIERS
5.2.5 BARGAINING POWER OF BUYERS
5.3 PRICING OVERVIEW, USD/TON (2018-2020)
5.4 IMPACT OF COVID-19 ON THE MICROCRYSTALLINE CELLULOSE INDUSTRY
5.4.1 OVERVIEW OF SUPPLY SCENARIO
5.4.2 IMPACT OF COVID-19 ON THE SUPPLY CHAIN OF MICROCRYSTALLINE CELLULOSE
5.4.2.1 RAW MATERIALS
5.4.2.1 MICROCRYSTALLINE CELLULOSE MANUFACTURERS
5.4.2.2 SALES & DISTRIBUTION CHANNELS
5.4.2.3 END USERS
5.4.3 QUALITATIVE ANALYSIS ON CHANGE IN DEMAND DUE TO COVID-19
5.4.4 IMPACT OF COVID ON GLOBAL ECONOMY
5.4.5 NUMBER OF COVID-19 CASES
5.4.6 MAJOR GOVERNMENT POLICIES TO COUNTER THE IMPACT OF COVID-19
5.4.6.1 US
5.4.6.1.1 FISCAL POLICIES
5.4.6.1.2 MONETARY AND MACRO-FINANCIAL
5.4.6.2 EUROPEAN UNION
5.4.6.2.1 FISCAL POLICIES
5.4.6.2.2 MONETARY AND MACRO-FINANCIAL
5.4.6.3 CHINA
5.4.6.3.1 FISCAL POLICIES
5.4.6.3.2 MONETARY AND MACRO-FINANCIAL
5.4.6.4 INDIA
5.4.6.4.1 FISCAL POLICIES
5.4.6.4.2 MONETARY AND MACRO-FINANCIAL
6 GLOBAL MICROCRYSTALLINE CELLULOSE MARKET, BY SOURCE
6.1 OVERVIEW
6.1.1 MICROCRYSTALLINE CELLULOSE: MARKET ESTIMATES & FORECAST BY SOURCE, 2018-2027
6.1.2 MICROCRYSTALLINE CELLULOSE: MARKET ESTIMATES & FORECAST BY SOURCE, 2018-2027
6.2 WOOD BASED
6.2.1 WOOD BASED: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
6.3 NON-WOOD BASED
6.3.1 NON-WOOD BASED: MARKET ESTIMATES & FORECAST BY REGION,2018-2027
7 GLOBAL MICROCRYSTALLINE CELLULOSE MARKET, BY END-USE INDUSTRY
7.1 OVERVIEW
7.1.1 MICROCRYSTALLINE CELLULOSE: MARKET ESTIMATES & FORECAST BY END-USE INDUSTRY, 2018-2027
7.1.2 MICROCRYSTALLINE CELLULOSE: MARKET ESTIMATES & FORECAST BY END-USE INDUSTRY, 2017-2025
7.2 PHARMACEUTICALS
7.2.1 PHARMACEUTICALS: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.2.2 PHARMACEUTICALS: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.3 FOOD & BEVERAGE
7.3.1 FOOD & BEVERAGE: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.3.2 FOOD & BEVERAGE: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.4 COSMETIC & PERSONAL CARE
7.4.1 COSMETIC & PERSONAL CARE: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.4.2 COSMETIC & PERSONAL CARE: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.5 OTHERS
7.5.1 OTHERS: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
7.5.2 OTHERS: MARKET ESTIMATES & FORECAST BY REGION, 2018-2027
8 GLOBAL MICROCRYSTALLINE CELLULOSE MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 RUSSIA
8.3.4 FRANCE
8.3.5 SPAIN
8.3.6 ITALY
8.3.7 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 CHINA
8.4.2 JAPAN
8.4.3 INDIA
8.4.4 SOUTH KOREA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 INDONESIA
8.4.7 THAILAND
8.4.8 REST OF ASIA-PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 GCC
8.5.2 ISRAEL
8.5.3 SOUTH AFRICA
8.5.4 REST OF MIDDLE EAST & AFRICA
8.6 LATIN AMERICA
8.6.1 BRAZIL
8.6.2 MEXICO
8.6.3 ARGENTINA
8.6.4 REST OF LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 COMPETITIVE OVERVIEW
9.2 GLOBAL MARKET STRATEGY ANALYSIS
9.3 COMPETITIVE BENCHMARKING
10 COMPANY PROFILES
10.1 DUPONT
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 ASAHI KASEI CORPORATION
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 ROQUETTE FRÈRES
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 MINGTAI CHEMICAL CO., LTD
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 ACCENT MICROCELL PVT. LTD
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 JRS PHARMA
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 PHARMATRANS-SANAQ AG
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 DFE PHARMA
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 WEI MING PHARMACEUTICAL MFG. CO., LTD
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 SIGACHI INDUSTRIES PVT.LTD.
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.10.6 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
